RJA
SRPT icon

Ross\Johnson & Associates’s Sarepta Therapeutics SRPT Stock Holding History

Ross\Johnson & Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72 Buy
+4
New +$76 ﹤0.01% 320

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ross\Johnson & Associates's SRPT Position: Q2 2026 in Review

Ross\Johnson & Associates opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 4 shares worth $72. The stake represents ﹤0.01% of the portfolio and ranks #320 among its holdings.

323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Ross\Johnson & Associates held 4 shares of Sarepta Therapeutics worth $72 as of Q2 2026.
  • Sarepta Therapeutics was a new Ross\Johnson & Associates position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #320 holding.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.